Cited by 76Computational Drug Discovery MethodsCell Image Analysis TechniquesMetabolomics and Mass Spectrometry Studies

Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints

Reisen, Felix, Sauty de Chalon, Amelie, Pfeifer, Martin, Zhang, Xian, Gabriel, Daniela, Selzer, Paul·2015·ASSAY and Drug Development Technologies

Abstract

High-content screening (HCS) is a powerful technique for monitoring phenotypic responses to treatments on a cellular and subcellular level. Cellular phenotypes can be characterized by multivariate image readouts such as shape, intensity, or texture. The corresponding feature vectors can thus be defined as HCS fingerprints that serve as a powerful biological compound descriptor. Therefore, clustering or classification of HCS fingerprints across compound treatments allows for the identification of similarities in protein targets or pathways. We developed an HCS-based profiling panel that serves as basis for characterizing the mode of action of compounds. This panel measures phenotypic effects in six different compartments of U-2OS cells, namely the nucleus, the cytoplasm, the endoplasmic reticulum, the Golgi apparatus, and the cytoskeleton. We profiled a set of 2,725 well-annotated compounds and clustered their corresponding HCS fingerprints to establish links between predominant cellular phenotypes and cellular processes and protein targets. We found various different clusters enriched for individual targets (e.g., HDAC, HSP90, TOP1, HMGCR, TUB), signaling pathways (e.g., PIK3/AKT/mTOR), or gene sets associated with diseases (e.g., psoriasis, leukemia). Based on this clustering we were able to identify novel compound-target associations for selected compounds such as a submicromolar inhibitory activity of Silmitasertib (a casein kinase inhibitor) on PI3K and mTOR.

Integrity signals

Registry

Crossref · 10.1089/adt.2015.656

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The Z-score oversimplifies interpretation and fails to capture changes in the modality of population-level feature distributions or subpopulations with different responses.

    “While the Z-score is commonly used to quantify phenotypic differences between treatment and control conditions23,28, it oversimplifies interpretation and will fail to capture changes in the modality of population-level feature distributions or subpopulations with different responses11.”
  • Using multiple marker panels allows surveying a broader spectrum of features and can reduce the risk of bleed-through between fluorescent channels.

    “Using multiple marker panels19,23 allows for surveying a broader spectrum of features and can reduce the risk of bleed-through between fluorescent channels depending on the assay design.”

The citation lists haven’t been fetched yet

References 50 · Cited by 76

Authors
Reisen, F., Sauty de Chalon, A., Pfeifer, M., Zhang, X., Gabriel, D., & Selzer, P.
Affiliations
  • Novartis (Switzerland) (CH)
  • Novartis Institutes for BioMedical Research
Venue
ASSAY and Drug Development Technologies
Published
2015-09
Volume
13
Issue
7
Pages
415-427
ISSN
  • 1540-658X (ISSN-L)
  • 1557-8127
OpenAlex
W1185588434
Cited by
76
References
50
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 11 · 2018: 9 · 2017: 8 · 2016: 9
FWCI
8.91
Type
journal article
Language
en
Open access
closed
Locations
  • Assay and Drug Development Technologies (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Cell Image Analysis Techniques
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords
mechanism of action, compound profiling, cell phenotype, U2OS cells, PI3K/AKT/mTOR pathway, silmitasertib, histone deacetylase inhibitors, Hsp90 inhibitors, topoisomerase I inhibitor, HMGCR inhibitors, tubulin polymerization inhibitors, drug repurposing
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Humans, Phenotype, Tubulin Modulators, Histone Deacetylase Inhibitors, High-Throughput Screening Assays, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review